RxDoctor Payments Data

Christie Konen, APRN

Family · Panama City, FLNPI 1992402085

Payments from drug & device makers

$3,547in general payments, 2019–2025

Across 163 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$511
  • BETA Bionics, Inc.$495
  • Medtronic$325
  • Novo Nordisk$312
  • AstraZeneca$277
  • Xeris Pharmaceuticals, Inc.$237
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,547100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,547 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$27,653
Medicare patients
127
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide67$99,966
OzempicSemaglutide51$75,816
JardianceEmpagliflozin26$38,989
FarxigaDapagliflozin Propanediol31$37,693
EliquisApixaban29$32,446
Tresiba Flextouch U-200Insulin Degludec14$27,348
TrulicityDulaglutide15$23,863
JanuviaSitagliptin Phosphate16$16,685
Tresiba Flextouch U-100Insulin Degludec25$16,421
Levemir FlexpenInsulin Detemir23$7,113
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,964
Novolog FlexpenInsulin Aspart13$3,873
Albuterol Sulfate HfaAlbuterol Sulfate41$1,965
Atorvastatin Calcium186$1,582
Levothyroxine Sodium149$1,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$511$123,82982 claims
Novo NordiskOzempic$312$75,81651 claims
Boehringer IngelheimJardiance$43$38,98926 claims
AstraZenecaFarxiga$277$37,69331 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$46$1,556149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.

Other family in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →